Product image of Linagliptina Zentiva (Linagliptin) supplied by GNH India

Linagliptina Zentiva

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptina Zentiva (Linagliptin)

Linagliptin, the active ingredient in Linagliptina Zentiva, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of blood glucose in adults with type 2 diabetes mellitus, helping to improve glycaemic control when combined with diet and exercise.

GNH India supplies Linagliptina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company emphasizes quality assurance, regulatory compliance, and reliable logistics for global distribution throughout.

Manufacturer / TM Owner

Zentiva Portugal, Lda

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is used to improve glycaemic control in the type 2 diabetes mellitus therapeutic pathway.

  • Type 2 diabetes mellitus (monotherapy): reduces fasting and post‑prandial glucose levels, leading to lower HbA1c.
  • Type 2 diabetes mellitus (combination therapy): added to metformin or other oral agents to achieve additional glycaemic reduction.
  • Type 2 diabetes mellitus (adjunct to diet and exercise): supports lifestyle measures to maintain target blood glucose.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By blocking DPP‑4, linagliptin raises circulating GLP‑1 and GIP levels, enhancing glucose‑dependent insulin secretion from pancreatic β‑cells and suppressing glucagon release from α‑cells, thereby reducing hepatic glucose production and lowering blood glucose concentrations.

Side Effects

Linagliptina Zentiva may be associated with several adverse reactions, which are grouped by frequency.

Common Side Effects

  • Upper respiratory tract infection
  • Nasopharyngitis
  • Headache
  • Dyspepsia

Serious or Rare Side Effects

  • Pancreatitis
  • Severe hypersensitivity reactions (e.g., angioedema, anaphylaxis)
  • Bullous skin disorders
  • Hypoglycaemia (when combined with insulin or sulfonylureas)

Precautions & Warnings

Before prescribing Linagliptina Zentiva, clinicians should consider the following precautions.

  • Renal impairment: dose adjustment is not required, but monitor renal function regularly.
  • Hepatic impairment: use with caution; monitor liver enzymes.
  • Elderly patients: monitor for hypoglycaemia when used with insulin or sulfonylureas.
  • Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
  • Drug interactions: review concomitant medications for potential DPP‑4 inhibitor interactions.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protect from moisture and light.

Avoid Interactions

Linagliptina Zentiva can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

  • Concomitant use with strong CYP3A4 inducers (e.g., rifampicin) may reduce linagliptin exposure.
  • Co‑administration with insulin or sulfonylureas increases risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Combination with other DPP‑4 inhibitors is not recommended; additive effect may increase adverse events.
  • Use with diuretics may affect blood glucose monitoring; adjust dose as needed.
  • Concurrent use with drugs that affect renal excretion (e.g., probenecid) may alter linagliptin levels.

Frequently Asked Questions

Linagliptina Zentiva contains linagliptin, a DPP‑4 inhibitor that is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents.

Linagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally breaks down the incretin hormones GLP‑1 and GIP. By inhibiting this enzyme, linagliptin raises incretin levels, enhancing insulin secretion and reducing glucagon release in a glucose‑dependent manner, which lowers plasma glucose.

The appropriate dose of Linagliptina Zentiva is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Linagliptina Zentiva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, or SGLT‑2 inhibitors in its mechanism of enhancing endogenous incretin activity. It generally has a low risk of hypoglycaemia when used alone and does not require dose adjustment in renal impairment, unlike some other oral agents.

Linagliptina Zentiva should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight and excessive heat to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious but rare adverse events include pancreatitis, severe hypersensitivity reactions such as angioedema or anaphylaxis, and bullous skin disorders. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or breathing difficulties.

Linagliptina Zentiva is contraindicated in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. Caution is also advised for individuals with a history of pancreatitis or severe renal/hepatic impairment, and it should be avoided in pregnancy unless clearly justified.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT